BioCentury | Jun 26, 2019
Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

...decreased levels of neurotoxic β amyloid and phosphorylated tau in brain tissue. Almirall S.A. markets Skilarence...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Autoimmune disease; musculoskeletal; neurology; renal

...associated with pulmonary arterial hypertension (PAH), Friedreich's ataxia and Alport syndrome. Almirall S.A. markets skilarence (LAS41008...
BioCentury | Oct 6, 2017
Company News

Almirall launches Skilarence in Europe

...Almirall S.A. (Madrid:ALM) launched Skilarence in Europe to treat moderate to severe chronic plaque psoriasis. Skilarence...
...NRF2). Almirall did not respond to inquiries. Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Autoimmune Shannon Lehnbeuter Skilarence Almirall Nuclear...
BioCentury | Jul 13, 2017
Company News

Almirall lowers guidance

...performance is “in line with expectations.” Acticlate is an oral tetracycline antibiotic. Last month, Almirall’s Skilarence...
...is under EMA review, from Merck & Co. Inc. (NYSE:MRK) (see BioCentury, April 3 ). Skilarence...
...subunit alpha ( IL23P19 ; IL-23A). Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Dermatology, Autoimmune Jaime De Leon Acticlate doxycycline LAS41008 MK-3222 Skilarence tildrakizumab Merck...
BioCentury | Jul 10, 2017
Financial News

Almirall sags after lowering guidance

...performance is “in line with expectations.” Acticlate is an oral tetracycline antibiotic. Last month, Almirall’s Skilarence...
...under EMA review, from Merck & Co. Inc. (NYSE:MRK) (see BioCentury Extra, March 24) . Skilarence...
...NRF2). Tildrakizumab is a humanized mAb against IL-23 subunit alpha ( IL23P19 ; IL-23A). Jaime De Leon Acticlate doxycycline LAS41008 MK-3222 Skilarence tildrakizumab Almirall...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...Intelligence Table: 2Q approvals2Q setbacks Selected 2Q approvals. Company Approval Almirall S.A. (Madrid:ALM) EC approves Skilarence...
BioCentury | Jul 6, 2017
Clinical News

EC approves Almirall's Skilarence for plaque psoriasis

...The European Commission approved Skilarence (LAS41008) from Almirall S.A.(Madrid:ALM) to treat moderate to severe chronic plaque...
...member states, Iceland and Norway. The company declined to disclose a wholesale acquisition cost (WAC). Skilarence...
...2 ( NFE2L2 ; NRF2). Almirall S.A. (Madrid:ALM), Barcelona, Spain Product: Skilarence (LAS41008) Business: Autoimmune Meghan Sullivan LAS41008 Skilarence Almirall...
BioCentury | Jun 27, 2017
Company News

EC approves Kevzara, Skilarence

...The European Commission approved two autoimmune drugs: Skilarence (LAS41008) from Almirall S.A. (Madrid:ALM) and Kevzara sarilumab...
...and Kevzara sarilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY). The EC approved Skilarence...
...plans to launch the drug next quarter in all EU member states, Iceland and Norway. Skilarence...
BioCentury | Oct 10, 2016
Clinical News

LAS41008: Phase III data

...BRIDGE trial in about 839 patients with moderate to severe chronic plaque psoriasis showed that LAS41008...
...PGA score of 0 or 1 point at week 16 (33% vs. 13%) vs. placebo. LAS41008...
...European Academy of Dermatology and Venereology meeting in Vienna. Almirall S.A. (Madrid:ALM), Barcelona, Spain Product: LAS41008...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...Tecfidera dimethyl fumarate, oral NFE2L2 pathway activator, to treat multiple sclerosis (MS). Almirall S.A. has LAS41008...
Items per page:
1 - 10 of 12